KemPharm, based in Coralville, IA, is a clinical-stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain. Its lead product candidate is KP201 (benzhydrocodone hydrochloride and acetaminophen) in development for acute moderate to moderately severe pain. The company also advances a portfolio of abuse-deterrent assets that utilize its LAT prodrug technology, including KP511 (a hydromorphone prodrug), KP606 (an oxycodone prodrug) and KP415 (a methylphenidate prodrug for ADHD). KemPharm plans to advance KP201 through potential FDA approval and into commercial development. To support clinical, regulatory and operational growth it entered a financing agreement with an investment fund managed by Deerfield Management for up to $60M. Leadership includes Travis C. Mickle (President & CEO) and Gordon K. "Rusty" Johnson (COO & CFO), and Deerfield’s Jonathan S. Leff joined the board as part of the financing. KemPharm focuses on discovering and developing new chemical entities for serious medical conditions. The company is advancing two lead candidates: KP201, a new chemical entity for pain based on its proprietary ligand-activated therapy platform with the possibility of reduced abuse potential, and KP106, a novel prodrug candidate for ADHD. The recent financing will fund Phase 1 proof-of-concept studies for both programs. Management involvement in the round indicates internal commitment to advancing the pipeline. The company announced it closed a $3.8M Series B financing to support these near-term clinical activities. No operating metrics beyond the pipeline and financing were disclosed in the article.

Total raised

$64M

Funding rounds

3

Latest round

Convertible Note

Latest activity

Jun 2014